



1645

#14

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE
AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:

ASSISTANT COMMISSIONER FOR PATENTS,
WASHINGTON, D.C. 20231, ON 12 February 2003

2/12/2003
ATTORNEY FOR APPLICANTS

DATE

RECEIVED

FEB 21 2003

TECH CENTER 1600/2900

Attorney Docket No. P50892

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tew, *et al.*

12 February 2003

Serial No.: 09/889,344

Group Art Unit No.: 1645

Filed: 20 January 2000

Examiner: Barbara A. Campbell

For: METHOD OF SITE SPECIFIC LABELING OF PROTEINS AND
USES THEREFOR

Assistant Commissioner for Patents
Washington, D.C. 20231


Filing of an Information Disclosure Statement under 37 C.F.R. §1.97(c) and
Certification under 37 C.F.R. §1.97(e)(1) or (e)(2)

Information Disclosure Statement. The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. Copies of each are enclosed, except for those references already part of the filewrapper. This statement is being filed with the required Certification and without any fee, in accordance with the provisions of 37 C.F.R. §1.97(c)(1) and (2), i.e., before a Final Action under 37 CFR §1.113 or a Notice of Allowance under 37 CFR §1.311.

Serial No.: 09/889,344
Group Art Unit No.: 1645

Statement of Certification. The undersigned hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Respectfully submitted,



Edward R. Gimmi
Attorney for Applicants
Registration No. 38,891

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-4478
Facsimile (610) 270-5090
N:\ERG\APPS\VP50892\usnat\IDS Search Report.doc



Sheet 1 of 1

Form 1 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P50892	SERIAL NO. 09/889,344
	APPLICANT Tew, et al.		
	FILING DATE 20 January 2000	GROUP 1645	

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AI	5,773,577	06/30/98	Joseph Cappello	530	350	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

RECEIVED
FEB 21 2003
TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AJ	Murthy, <i>et al.</i> , "Residue Gln-30 of Human Erythrocyte Anion Transporter Is a Prime Site for Reaction with Intrinsic Transglutaminase," <i>The Journal of Biological Chemistry</i> , 269(36): 22907-22911 (1994).
	AK	Copy of Partial EP Search Report.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

N:\ERG\APPS\P50892\usnat1\1449 Search Report.doc